Electromed Financials
This page shows Electromed (ELMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Electromed has an operating margin of 15.1%, meaning the company retains $15 of operating profit per $100 of revenue. This strong profitability earns a score of 75/100, reflecting efficient cost management and pricing power. This is up from 12.0% the prior year.
Electromed's revenue surged 17.0% year-over-year to $64.0M, reflecting rapid business expansion. This strong growth earns a score of 77/100.
Electromed carries a low D/E ratio of 0.25, meaning only $0.25 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.31, Electromed holds $4.31 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Electromed converts 17.4% of revenue into free cash flow ($11.1M). This strong cash generation earns a score of 87/100.
Electromed earns a strong 17.4% return on equity (ROE), meaning it generates $17 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 70/100. This is up from 11.6% the prior year.
Electromed scores 14.73, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($205.3M) relative to total liabilities ($10.6M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Electromed passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Electromed generates $1.51 in operating cash flow ($11.4M OCF vs $7.5M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Electromed generated $64.0M in revenue in fiscal year 2025. This represents an increase of 17.0% from the prior year.
Electromed's EBITDA was $10.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 45.9% from the prior year.
Electromed generated $11.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 26.8% from the prior year.
Electromed reported $7.5M in net income in fiscal year 2025. This represents an increase of 46.3% from the prior year.
Electromed earned $0.85 per diluted share (EPS) in fiscal year 2025. This represents an increase of 46.6% from the prior year.
Electromed held $15.3M in cash against $0 in long-term debt as of fiscal year 2025.
Electromed had 8M shares outstanding in fiscal year 2025. This represents a decrease of 3.3% from the prior year.
Electromed's gross margin was 78.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.8 percentage points from the prior year.
Electromed's operating margin was 15.1% in fiscal year 2025, reflecting core business profitability. This is up 3.1 percentage points from the prior year.
Electromed's net profit margin was 11.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 2.4 percentage points from the prior year.
Electromed's ROE was 17.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 5.9 percentage points from the prior year.
Electromed invested $996K in research and development in fiscal year 2025. This represents an increase of 51.8% from the prior year.
Electromed spent $10.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 3536.4% from the prior year.
Electromed invested $262K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 8.7% from the prior year.
ELMD Income Statement
| Metric | Q2'26 | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.9M0.0% | $18.9M+11.9% | $16.9M+7.7% | $15.7M-3.5% | $16.3M+10.8% | $14.7M+5.7% | $13.9M+1.3% | $13.7M |
| Cost of Revenue | $4.1M0.0% | $4.1M+10.5% | $3.7M+6.8% | $3.5M-4.8% | $3.6M+14.2% | $3.2M-8.9% | $3.5M+11.0% | $3.1M |
| Gross Profit | $14.8M0.0% | $14.8M+12.3% | $13.2M+7.9% | $12.2M-3.2% | $12.6M+9.9% | $11.5M+10.7% | $10.4M-1.5% | $10.5M |
| R&D Expenses | $384K0.0% | $384K+59.3% | $241K-13.0% | $277K+10.4% | $251K+51.2% | $166K-0.6% | $167K+56.1% | $107K |
| SG&A Expenses | $10.8M0.0% | $10.8M+5.1% | $10.3M+4.8% | $9.8M-0.2% | $9.8M+4.8% | $9.4M+12.1% | $8.4M+2.4% | $8.2M |
| Operating Income | $3.6M0.0% | $3.6M+35.6% | $2.7M+24.8% | $2.1M-15.8% | $2.5M+31.2% | $1.9M+5.3% | $1.8M-18.6% | $2.3M |
| Interest Expense | N/A | N/A | N/A | N/A | $152K-22.1% | $195K+62.5% | $120K+25.0% | $96K |
| Income Tax | $968K0.0% | $968K+44.9% | $668K+70.8% | $391K-46.1% | $726K+10.2% | $659K+40.8% | $468K-31.7% | $685K |
| Net Income | $2.8M0.0% | $2.8M+29.3% | $2.1M+13.0% | $1.9M-3.9% | $2.0M+33.5% | $1.5M-1.3% | $1.5M-10.8% | $1.7M |
| EPS (Diluted) | $0.320.0% | $0.32+28.0% | $0.25+19.0% | $0.21-4.5% | $0.22+37.5% | $0.16-5.9% | $0.17-10.5% | $0.19 |
ELMD Balance Sheet
| Metric | Q2'26 | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $54.9M0.0% | $54.9M+2.4% | $53.6M+2.2% | $52.5M+0.3% | $52.3M+6.9% | $48.9M0.0% | $48.9M+4.1% | $47.0M |
| Current Assets | $45.6M0.0% | $45.6M+2.3% | $44.6M+0.8% | $44.2M0.0% | $44.2M+7.8% | $41.0M-0.8% | $41.3M+5.2% | $39.3M |
| Cash & Equivalents | $13.8M0.0% | $13.8M-2.3% | $14.1M-7.4% | $15.2M-6.1% | $16.2M+17.1% | $13.9M+18.4% | $11.7M+12.2% | $10.4M |
| Inventory | $3.5M0.0% | $3.5M-8.3% | $3.8M+27.1% | $3.0M-3.7% | $3.1M-10.3% | $3.4M-17.8% | $4.2M-12.2% | $4.8M |
| Accounts Receivable | $26.3M0.0% | $26.3M+6.1% | $24.8M+5.6% | $23.4M+2.9% | $22.8M+1.8% | $22.4M-6.4% | $23.9M+4.0% | $23.0M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $9.5M0.0% | $9.5M+6.8% | $8.9M+4.2% | $8.5M-1.8% | $8.7M+16.7% | $7.4M+16.8% | $6.4M-4.0% | $6.6M |
| Current Liabilities | $9.4M0.0% | $9.4M+7.0% | $8.8M+2.9% | $8.5M-1.8% | $8.7M+16.8% | $7.4M+17.3% | $6.3M-3.8% | $6.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $45.4M0.0% | $45.4M+1.6% | $44.7M+1.8% | $43.9M+0.8% | $43.6M+5.1% | $41.5M-2.5% | $42.5M+5.5% | $40.3M |
| Retained Earnings | $22.3M0.0% | $22.3M-0.1% | $22.3M-1.1% | $22.6M-0.1% | $22.6M+9.7% | $20.6M-6.9% | $22.1M+7.2% | $20.6M |
ELMD Cash Flow Statement
| Metric | Q2'26 | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $3.2M+5.6% | $3.0M+1690.5% | $169K-91.9% | $2.1M-34.2% | $3.2M+36.5% | $2.3M+70.9% | $1.4M-61.1% | $3.5M |
| Capital Expenditures | $886K+39.7% | $634K+151.6% | $252K+264.7% | -$153K-165.7% | $233K+529.7% | $37K-56.5% | $85K+19.7% | $71K |
| Free Cash Flow | $2.3M-3.5% | $2.4M+2981.9% | -$83K-104.3% | $1.9M-34.2% | $2.9M+28.4% | $2.3M+79.5% | $1.3M-62.8% | $3.4M |
| Investing Cash Flow | $923K+240.7% | -$656K-145.7% | -$267K-282.9% | $146K+161.6% | -$237K-308.6% | -$58K+55.0% | -$129K-48.3% | -$87K |
| Financing Cash Flow | $3.8M+240.0% | -$2.7M-150.2% | -$1.1M+66.6% | -$3.2M-492.6% | -$543K+87.8% | -$4.5M-8076.8% | $56K+115.4% | $26K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $3.8M+36.3% | $2.8M+175.5% | $1.0M-44.1% | $1.8M | $0-100.0% | $4.5M | N/A | $0 |
ELMD Financial Ratios
| Metric | Q2'26 | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.4%0.0pp | 78.4%+0.3pp | 78.1%+0.2pp | 78.0%+0.3pp | 77.7%-0.7pp | 78.3%+3.5pp | 74.9%-2.2pp | 77.0% |
| Operating Margin | 19.2%0.0pp | 19.2%+3.4pp | 15.8%+2.2pp | 13.6%-2.0pp | 15.6%+2.4pp | 13.2%-0.1pp | 13.3%-3.3pp | 16.5% |
| Net Margin | 14.6%0.0pp | 14.6%+2.0pp | 12.7%+0.6pp | 12.1%-0.1pp | 12.1%+2.1pp | 10.1%-0.7pp | 10.8%-1.5pp | 12.2% |
| Return on Equity | 6.1%0.0pp | 6.1%+1.3pp | 4.8%+0.5pp | 4.3%-0.2pp | 4.5%+1.0pp | 3.5%+0.0pp | 3.5%-0.6pp | 4.2% |
| Return on Assets | 5.0%0.0pp | 5.0%+1.0pp | 4.0%+0.4pp | 3.6%-0.2pp | 3.8%+0.8pp | 3.0%-0.0pp | 3.0%-0.5pp | 3.6% |
| Current Ratio | 4.860.0 | 4.86-0.2 | 5.09-0.1 | 5.19+0.1 | 5.10-0.4 | 5.53-1.0 | 6.53+0.6 | 5.97 |
| Debt-to-Equity | 0.210.0 | 0.21+0.0 | 0.200.0 | 0.190.0 | 0.20+0.0 | 0.18+0.0 | 0.15-0.0 | 0.16 |
| FCF Margin | 12.2%-0.4pp | 12.7%+13.1pp | -0.5%-12.7pp | 12.3%-5.7pp | 17.9%+2.5pp | 15.5%+6.4pp | 9.1%-15.7pp | 24.8% |
Similar Companies
Frequently Asked Questions
What is Electromed's annual revenue?
Electromed (ELMD) reported $64.0M in total revenue for fiscal year 2025. This represents a 17.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Electromed's revenue growing?
Electromed (ELMD) revenue grew by 17% year-over-year, from $54.7M to $64.0M in fiscal year 2025.
Is Electromed profitable?
Yes, Electromed (ELMD) reported a net income of $7.5M in fiscal year 2025, with a net profit margin of 11.8%.
What is Electromed's earnings per share (EPS)?
Electromed (ELMD) reported diluted earnings per share of $0.85 for fiscal year 2025. This represents a 46.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Electromed's EBITDA?
Electromed (ELMD) had EBITDA of $10.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Electromed's gross margin?
Electromed (ELMD) had a gross margin of 78.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Electromed's operating margin?
Electromed (ELMD) had an operating margin of 15.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Electromed's net profit margin?
Electromed (ELMD) had a net profit margin of 11.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Electromed's return on equity (ROE)?
Electromed (ELMD) has a return on equity of 17.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Electromed's free cash flow?
Electromed (ELMD) generated $11.1M in free cash flow during fiscal year 2025. This represents a 26.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Electromed's operating cash flow?
Electromed (ELMD) generated $11.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Electromed's total assets?
Electromed (ELMD) had $53.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Electromed's capital expenditures?
Electromed (ELMD) invested $262K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Electromed spend on research and development?
Electromed (ELMD) invested $996K in research and development during fiscal year 2025.
Does Electromed buy back shares?
Yes, Electromed (ELMD) spent $10.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
How many shares does Electromed have outstanding?
Electromed (ELMD) had 8M shares outstanding as of fiscal year 2025.
What is Electromed's current ratio?
Electromed (ELMD) had a current ratio of 4.31 as of fiscal year 2025, which is generally considered healthy.
What is Electromed's debt-to-equity ratio?
Electromed (ELMD) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Electromed's return on assets (ROA)?
Electromed (ELMD) had a return on assets of 14.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Electromed's Altman Z-Score?
Electromed (ELMD) has an Altman Z-Score of 14.73, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Electromed's Piotroski F-Score?
Electromed (ELMD) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Electromed's earnings high quality?
Electromed (ELMD) has an earnings quality ratio of 1.51x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Electromed?
Electromed (ELMD) scores 85 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.